Kymera weakness a buying opportunity, says Stifel

finance.yahoo.com/news/kymera-weakness-buying-opportunity-says-144542066.html

In This Article:
Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following “a slate of updates,” including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new…

This story appeared on finance.yahoo.com, 2025-06-26 14:45:42.
The Entire Business World on a Single Page. Free to Use →